niacinamide has been researched along with mitoxantrone in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Balzarini, J; Chen, YA; Chueh, PJ; Dezhenkova, LG; Glazunova, VA; Lee, YH; Preobrazhenskaya, MN; Shchekotikhin, AE; Shtil, AA; Tatarskiy, VV; Tikhomirov, AS; Yeh, CA | 1 |
| Hou, T; Li, Y; Ma, Y; Peng, H; Ren, Z; Wei, Y; Zhao, Q | 1 |
| Bitran, JD; Cygan, P; Galvez, AG; Lestingi, TM; Meyer, A; Nabhan, C; Tolzien, K | 1 |
1 trial(s) available for niacinamide and mitoxantrone
| Article | Year |
|---|---|
Role of sorafenib in overcoming resistance of chemotherapy-failure castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mitoxantrone; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms, Castration-Resistant; Sorafenib; Survival Analysis; Taxoids; Treatment Failure | 2014 |
3 other study(ies) available for niacinamide and mitoxantrone
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Synthesis and Characterization of 4,11-Diaminoanthra[2,3-b]furan-5,10-diones: Tumor Cell Apoptosis through tNOX-Modulated NAD(+)/NADH Ratio and SIRT1.
Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Mice; NAD; NADH, NADPH Oxidoreductases; Sirtuin 1; Structure-Activity Relationship | 2015 |
New use for an old drug: inhibiting ABCG2 with sorafenib.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Intracellular Space; Mitoxantrone; Molecular Conformation; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Binding; Pyridines; Signal Transduction; Sorafenib | 2012 |